Hyun Chong Woo

This inventor holds 7 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 7 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Merck Canada Inc.. Active years: 2013-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hyun Chong Woo. Retrieved from https://idiyas.com/inventor/hyun-chong-woo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 12.7

ph-index = 2

Forward Citations = 5(Granted Patents)

Location History:

Brookline, MA (US) (2013)
Natick, MA (US) (2015 - 2017)

Company Filing History:

7 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2013-2017

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9745295 - Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors (2017-08-29),

2. 9598405 - Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors (2017-03-21),

3. 9394282 - Pyrazole carboxamides as Janus kinase inhibitors (2016-07-19),

4. 9328099 - Cyanomethylpyrazole carboxamides as janus kinase inhibitors (2016-05-03),

5. 8993756 - Pyrrolopyrimidines as janus kinase inhibitors (2015-03-31),

6. 8937077 - Bicyclic diamines as janus kinase inhibitors (2015-01-20),

7. 8367706 - Inhibitors of janus kinases (2013-02-05),

Title: Hyun Chong Woo: Innovator in Spleen Tyrosine Kinase Inhibition

Introduction

Hyun Chong Woo is a distinguished inventor based in Natick, MA, USA, known for his significant contributions to the field of medicinal chemistry. With a total of seven patents to his name, he has made noteworthy advancements in developing compounds aimed at treating diseases mediated by Spleen Tyrosine Kinase (Syk).

Latest Patents

Among his latest patents, Hyun Chong Woo has developed innovative compounds including thiazole-substituted aminoheteroaryls and thiazole-substituted aminopyridines. The first patent details compounds of a specific formula, along with their pharmaceutically acceptable salts. These compounds demonstrate potential for use in pharmaceutical compositions targeting conditions associated with Spleen Tyrosine Kinase. Similarly, his second patent focuses on thiazole-substituted aminopyridines, providing compounds with similar medicinal applications aimed at Syk-mediated diseases.

Career Highlights

Throughout his career, Woo has garnered experience working at prominent pharmaceutical companies such as Merck Sharp & Dohme Corporation and Merck Canada Inc. His work in these organizations has been pivotal to his research and innovation in drug development, specifically in relation to cancer therapies.

Collaborations

Hyun Chong Woo has collaborated with notable colleagues, including Matthew Christopher and Joon Jung. These partnerships have likely enriched his research endeavors, promoting the advancement of innovative solutions in the pharmaceutical sector.

Conclusion

Hyun Chong Woo's innovative work continues to contribute to the field of medicine, particularly in developing treatments that target critical pathways in disease management. His dedication to research and collaboration exemplifies the spirit of innovation that propels advancements in healthcare.

Profile summary based on public USPTO records.